Recent Advances in the Treatment Of Newly Diagnosed Multiple Myeloma
Presented by Edward Libby,(1) MD, and Josh Epworth,(2) ARNP
From (1)University of Washington and Washington University Medical Center, Seattle, Washington; (2)Seattle Cancer Care Alliance, Seattle, Washington
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2020;11(3):301–305 |
© 2020 Harborside™
Edward Libby, MD, and Josh Epworth, ARNP, interpreted data on current and novel treatments, discussed how to select initial therapy based on patient risk and in alignment with guidelines and best practices, and evaluated the use of minimal residual disease testing in patients with multiple myeloma.
For access to the full length article, please sign in